Probiotic Pediococcus acidilactici PA53 Improves Sleep and Mood in Older Adults
A recent clinical trial suggests that the probiotic strain Pediococcus acidilactici PA53 may significantly improve mood, sleep quality, and digestion among older adults aged 55 to 70. Conducted by researchers in China, the study involved 75 healthy participants who were divided into two groups: one receiving a daily dose of 30 billion colony-forming units (CFUs) of the probiotic and the other a placebo. After eight weeks, the results from the 69 participants who completed the trial revealed encouraging findings. Those taking the probiotic reported a 12.7% increase in happiness scores and a 23% improvement in sleep quality, as measured by the Pittsburgh Sleep Quality Index.
In terms of digestive health, participants on the probiotic experienced a 9.5% reduction in digestive symptoms, and stool consistency improved by 28% according to the Bristol Stool Scale. While stress levels showed only a modest decrease of 3.3% in the probiotic group, this change was not statistically significant. However, the probiotic group still outperformed the placebo group in overall well-being.
The study also examined underlying biological changes. Blood tests indicated a significant reduction in two markers of chronic inflammation, IL-6 and TNF-α, among those taking the probiotic. Additionally, levels of IL-25, a cytokine associated with intestinal repair and immune balance, increased notably. Analysis of the gut microbiomes of participants showed that supplementation with PA53 promoted the growth of beneficial bacteria, with Ruminococcus doubling in abundance and Blautia and Faecalibacterium also increasing significantly.
Insights from Recent Research on Probiotic Strain PA53
Fei Xu, the study's corresponding author, noted that previous research had established the safety of this strain and its ability to survive stomach acid and bile, paving the way for human trials. He emphasized that while this study provides early clinical evidence supporting the use of PA53 in older adults, it is not definitive. The authors acknowledged that not all psychological measures showed statistically significant improvements and cautioned against over-interpreting the mood results. Xu pointed out that the trial's relatively small size and short duration mean that larger, long-term studies are necessary to confirm these findings.
Exploring the Practical Implications of PA53 for Older Adults
Currently, PA53 is not widely available in stores, as it is developed and marketed by China's Wecare Probiotics, which provided the product and placebo for the trial but did not fund the study or control the data. Dietitians recommend ensuring that probiotic labels specify the exact strain, as benefits can vary significantly between different strains. Furthermore, since the beneficial bacteria in this trial thrive on fiber, incorporating more vegetables, beans, and whole grains into the diet can support their growth naturally. As with any new supplement, consulting with a healthcare provider before starting is advisable.
This trial adds to the growing body of evidence suggesting that gut health extends beyond digestion, offering a potential alternative for older adults seeking non-prescription solutions for sleep and mood enhancement. A simple probiotic could provide a valuable option for those looking to improve their quality of life without resorting to medications.




